Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma

Wspolczesna Onkologia

Volumn 19, Issue 4, 2015, Pages 290-299

  Lukesova, Sarka ^a   Vroblova, Vladimira ^b   Tosner, Jindrich ^b   Kopecky, Jindrich ^b   Sedlakova, Iva ^b   Čermáková, Eva ^a   Vokurkova, Doris ^b   Kopecky, Otakar ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Flow cytometry; NK cells; NKG2D; Ovarian cancer; Tumour infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLOW CYTOMETER; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALIGNANT ASCITES; MIDDLE AGED; NATURAL KILLER CELL; OVARY CARCINOMA; PHENOTYPE; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

EID: 84942605792     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2015.54388     Document Type: Article

References (59)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Miedzinska-Maciejewska M, Wcislo G, Bodnar L. The modulation of multidrug resistance in ovarian cancer patiens. Współcz Onkol 2004; 8: 457-65.
3. Sikora J. The role of TCRζ expression in immunosuppression induced by tumour. Współcz Onkol 2009; 13: 457-65.
4. Freedman RS, Kudelka AP, Kavanagh JJ, et al. Differential expression of CD3zeta message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma. Clin Cancer Res 2000; 6: 2268-78.
5. Cózar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, Ruiz-Cabello Osuna F. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 2005; 54: 858-66.
6. Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A. Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization. Clin Dev Immunol 2010; 2010: 791603, doi: 10.1155/2010/791603.
7. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7: 651-8.
8. Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
9. Maleno I, Cabrera CM, Cabrera T, Paco L, López-Nevot MA, Collado A, Ferrón A, Garrido F. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004; 56: 244-53.
10. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
11. Ishigami S, Natsugoe S, Tokuda K, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159: 103-8.
12. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
13. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8-tumor-infiltrating lymphocytes and a high CD8-regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-43.
14. Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 2007; 122: 418-29.
15. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson B, Belinson J. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22: 3120-5.
16. Kryczek I, Liu R, Wang G, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69: 3995-4000.
17. Bamias A, Tsiatas ML, Kafantari E, et al. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 2007; 106: 75-81.
18. Tsiatas ML, Gyftaki R, Liacos C, Politi E, Rodolakis A, Dimopoulos MA, Bamias A. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. Int J Gynecol Cancer 2009; 19: 1329-34.
19. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009; 58: 449-59.
20. Vermeij R, de Bock GH, Leffers N, et al. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with Wilms tumor protein 1 overexpression. J Immunother 2011; 34: 516-23.
21. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94: 1003-9.
22. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 2006; 119: 254-64.
23. Chen LL, Ye F, Lü WG, Yu Y, Chen HZ, Xie X. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res 2009; 35: 212-8.
24. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002; 8:1108-14.
25. Horalka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-80.
26. Tomšová M, Melichar B, Sedláková I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108: 415-20.
27. Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC. The distinct contributions of murine T cell receptor(TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003; 198: 747-55.
28. Girardi M. Immunosurveillance and Immunoregulation by γδ T Cells. J Invest Dermatol 2006; 126: 25-31.
29. Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H, Sekine I. Systematic characterisation of human CD8+ T cells with natural killer cell markers in comparasion with natural cells and normal CD8+ T cells. Imunology 2001; 103: 281-90.
30. Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P. The repertoire of killer cell Ig-like receptor and D94:NKG2A receptors in T cells: Clones sharing identical αβ TcR rearrangement express highly diverse killer cell Ig-like receptor patterns J Immunol 2001; 166: 3923-32.
31. Van den Hove LE, Van Gool SW, Vandenberghe P, Boogaerts MA, Ceuppens JL. CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia 1998; 12: 1573-82.
32. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330: 827-30.
33. Bianchi G, Borgonovo G, Pistoia V, Raffaghello L. Immunosuppressive cells and tumour microenvironment: Focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol 2011; 26: 941-51.
34. Lazennec G, Jorgensen Ch. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008; 26: 1387-94.
35. Miki-Hosokawa T, Hasegawa A, Iwamura C, et al. CD69 controls the pathogenesis of allergic airway inflammation. J Immunol 2009; 183: 8203-15.
36. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
37. 37. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 8326-31.
38. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Cytotoxic T-lymphocyte Immunotherapy for ovaria cancor: A pilot study. J Immunother 2012; 35: 196-204.
39. Linnebacher M. Tumor infiltrating Bcells come into vogue. World J Gastroenterol 2013; 19: 8-11.
40. Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012; 18: 3281-92.
41. Santin AD, Hermonat PL, Ravaggi A, et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Incest 2001; 51: 254-61.
42. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes; biology, development and function. Cancer Immunol Immunother 2004; 53: 176-86.
43. Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res 2010; 29: 8. doi: 10.1186/1757-2215-3-8.
44. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56 bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101: 3052-7.
45. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD- 56bright natural killer (NK) cells: an important NK cell subset. Imunology 2009; 126: 458-65.
46. 46. Romagnnani C, Juelke K, Falco M, et al. CD56 bright CD16- killer Ig like receptor - NK cells display longer telomeres and acquire feature of CD56 dim NK cells upon activation. J Immunol 2007; 178: 4947-55.
47. Patankar MS, Jing Y, Morrison JC, et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA 125. Gynecol Oncol 2005; 99: 704-13.
48. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Brehrens G, Sykora KW, Schmidt RE. CD56 bright NK cells differ KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001; 31: 3121-6.
49. McFarland BJ, Kortemme T, Yu SF, Baker D, Strong RK. Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure 2003; 11: 411-22.
50. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991; 173: 1017-20.
51. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 2002; 3: 1150-5.
52. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998; 391: 703-7.
53. Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A 2005; 102: 7641-6.
54. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-85.
55. Long EO. Negative signaling by inhibitory receptor: the NK cell paradigm. Immunol Rev 2008; 224: 70-84.
56. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HK, Kieslling R, Malmberg KJ. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK Cells. J Immunol 2009; 183: 4921-30.
57. Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 2006; 176: 905-13.
58. Barber A, Sentman CL. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol 2009; 183: 2365-72.
59. Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol 2009; 183: 6939-47.